Panacea Biotec's EmulsiPan listed in CEPI Adjuvant Library to support vaccine development
EmulsiPan is an oil-in-water emulsion adjuvant created through the nano-emulsification of squalene, surfactants, and buffers. Squalene is a naturally occurring biodegradable and biocompatible triterpene hydrocarbon found in plants and humans. EmulsiPan is supplied as a ready-to-use sterile emulsion in 10 mL USP Type I glass vials, intended for research purposes. It is stable for over two years when stored between 2-8°C.
The global market for adjuvants is projected to exceed $4.8 billion by 2028, driven by applications in vaccines and biological therapies, including oncology. Oil-in-water emulsion adjuvants, such as EmulsiPan, are commonly used in commercial vaccines, including influenza vaccines. EmulsiPan's availability without licensing fees provides an accessible option for vaccine developers.
EmulsiPan has been used in various preclinical studies and collaborative research projects. Notably, it was applied in non-human primate challenge studies for Sarbecoronavirus vaccine candidates at the California Institute of Technology (Caltech) and in Betacoronavirus vaccine development programs in partnership with BRIC-Translational Health Science and Technology Institute (THSTI), funded by CEPI. These studies demonstrate its adaptability and effectiveness in vaccine research.
Developed in 2009 and first commercialized as part of Panacea Biotec's H1N1 vaccine, PandyFlu, EmulsiPan has since become a platform adjuvant for multiple vaccine candidates. Panacea Biotec established a cGMP manufacturing facility for EmulsiPan, ensuring consistent quality and regulatory compliance.
The inclusion of EmulsiPan in the CEPI Adjuvant Library confirms it has undergone scientific evaluation and meets standards necessary to support human vaccine development. This listing is expected to increase access for researchers and companies interested in using EmulsiPan for commercial or research applications.
By offering a stable, ready-to-use formulation and removing licensing fees, Panacea Biotec aims to facilitate equitable access to vaccine adjuvants and contribute to global preparedness for future epidemics and pandemics.
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at BusinessUpturn.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
12 hours ago
- Business Upturn
Aster DM acquires additional 13% stake in DRCM for Rs 63 crore, enters lease agreement for 500-bed hospital in Bengaluru
Aster DM Healthcare has announced key strategic developments aimed at expanding its footprint in India. In a meeting held on July 30, 2025, the company's Investment and Finance Committee approved two major decisions: increasing its stake in a key subsidiary and signing a lease for a new super-specialty hospital in Bengaluru. The company will acquire an additional 13% equity in Dr. Ramesh Cardiac & Multispecialty Hospital Pvt Ltd (DRCM), increasing its total shareholding from 57.49% to 70.49%. This INR 63.01 crore cash deal comes as part of a put option exercised by DRCM's promoters under the 2016 shareholders agreement. DRCM, based in Andhra Pradesh, reported a turnover of ₹258 crore in FY25. In a parallel move, Aster has entered into a lease agreement with KEMWELL Private Limited for a composite property in Yeshwanthpur, Bengaluru. The company plans to set up a 500-bed super-specialty hospital on the site, with operations expected to begin in H2 FY28-29. This ₹580 crore investment will be funded through internal accruals and bank loans. The new hospital will serve the fast-growing northwest Bengaluru corridor, offering advanced tertiary care with excellent metro and rail connectivity. These initiatives reflect Aster's continued focus on expanding its healthcare network across India and strengthening its position in the high-growth southern market. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
12 hours ago
- Business Upturn
Dr. Reddy's Laboratories shares in focus as company sees double-digit sales growth for FY26
Dr. Reddy's Laboratories shares were in the spotlight on Wednesday after the company's management expressed confidence in achieving strong financial growth in FY26. As of 11:24 AM, the shares were trading 0.67% lower at Rs 1,291.10. In a recent update, the company's Chief Financial Officer stated that Dr. Reddy's is aiming for double-digit sales growth and a robust 25% EBITDA margin for the current financial year. Dr. Reddy's Laboratories shares traded in a narrow range today. The stock opened at ₹1,298.10, slightly lower than its previous close of ₹1,299.80. During the session, it touched an intraday low of ₹1,277.70 and a high of ₹1,298.10. Over the past 52 weeks, the stock has seen a low of ₹1,020.00 and a high of ₹1,421.49. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
2 days ago
- Business Upturn
Cosmo First's Zigly acquires Dr. Santa Animal Healthcare, launches multi-speciality pet care centre in Whitefield, Bengaluru
By Aman Shukla Published on July 28, 2025, 16:36 IST Zigly, India's first tech-enabled omni-channel pet care brand and a part of Cosmo First, has announced the strategic acquisition of Dr. Santa Animal Healthcare, a reputed veterinary clinic based in Bengaluru. The acquisition marks the launch of Zigly's full-fledged 24×7 multi-speciality pet hospital in Whitefield, reinforcing its commitment to premium pet wellness services. The Whitefield centre will offer round-the-clock veterinary care, surgeries, diagnostics, grooming spa, and curated pet products from Applod, FurPro, and Zigly Lifestyle. Dr. Santa, with over five years of experience and Rs 2.23 crore (unaudited) in FY25 revenue, brings a strong client base and operational legacy. With this expansion, Zigly now operates six centres in Bengaluru—HSR Layout, JP Nagar, New Bel Road, Koramangala, Karthik Nagar, and Whitefield. The acquisition includes all assets, employees, and customer data, ensuring a seamless transition for existing pet parents. Pankaj Poddar, Group CEO of Cosmo First, said the move strengthens Zigly's mission to deliver holistic and modern pet care. The new centre is located at Pattandur Agrahara Village, Ambedkar Nagar, Whitefield. This launch further positions Zigly as a leader in India's growing premium pet care segment, offering tech-enabled, comprehensive wellness solutions for pets. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
